Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Stem Cell Therapeutics Corp.    R5W   CA8585721001

SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Stem Cell Therapeutics Corp. : Stem Cell Therapeutics Completes Trillium Merger and Issues Stock Options

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/10/2013 | 03:45am CET

FOR IMMEDIATE RELEASE TSX-Venture Exchange: SSS

STEM CELL THERAPEUTICS COMPLETES TRILLIUM MERGER AND ISSUES STOCK OPTIONS

Toronto, Canada, April 9, 2013 - Stem Cell Therapeutics Corp. (TSX-V:SSS) ("SCT"), a life sciences company developing stem cell-related technologies, today announced that it has completed its merger with Trillium Therapeutics Inc. ("Trillium") previously announced on February 4, 2013. The shareholders of Trillium voted overwhelmingly to support the merger.

The company also announced the issuance of 2,560,197 stock options under its stock option plan to directors, officers and employees reflecting the addition of the executives and staff of the merged entity. The options have an exercise price of $0.25 and a term of ten years. The issuance of stock options is subject to acceptance by the TSX Venture exchange.

About Stem Cell Therapeutics:

Stem Cell Therapeutics Corp. (TSX-V: SSS) develops stem cell-based therapeutics through partnerships with research institutions and technology transfer organizations. SCT's objectives include the sourcing and acquisition of stem cell-related development opportunities, and securing capital for the advancement of its licensed or acquired products. The Corporation's intended corporate acquisitions and licensed acquisitions are positioning it principally in the field of cancer stem cell therapeutic development. SCT is a member of the Centre for Commercialization of Regenerative Medicine consortium. For more information, visit: www.stemcellthera.com

Forward Looking Statements

This press release may contain forward-looking statements, which reflect SCT's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the satisfaction of the conditions precedent to the exercise of the option to acquire a license to certain technologies owned by University Health Network; the exercise of the option to acquire a license to
certain technologies owned by University Health Network; the execution and delivery of a definitive license agreement with University Health Network if SCT determines to exercise the University Health Network option; changing market conditions; the successful and timely completion of pre-clinical and clinical studies; the establishment of corporate alliances; the impact of competitive products and pricing; new product development risks; uncertainties related to the regulatory approval process or the ability to obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or to meet commercial demand; and other risks detailed from time to time in SCT's ongoing quarterly and annual reporting, including in the base shelf prospectus dated March 1, 2011 and any prospectus supplement. Except as required by applicable securities laws, SCT undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FOR FURTHER INFORMATION PLEASE CONTACT: Niclas Stiernholm

Chief Executive Officer

Stem Cell Therapeutics Corp. nstiernholm@stemcellthera.com

+1 416 595 0627 www.stemcellthera.com

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on STEM CELL THERAPEUTICS COR
02/24 TRILLIUM THERAPEUTICS : Provides Additional Details on ASCO-SITC Conference Pres..
02/15 TRILLIUM THERAPEUTICS : To Present At Investor And Scientific Conferences In Feb..
02/15 TRILLIUM THERAPEUTICS : Outlines Anticipated Activities and Milestones for 2017
02/15 TRILLIUM THERAPEUTICS : Doses First Patient With TTI-621 In Phase 1 Solid Tumor ..
02/15 TRILLIUM THERAPEUTICS : to Present New Data from TTI-621 Phase 1 Trial
02/07 TRILLIUM THERAPEUTICS : to Present at Investor and Scientific Conferences in Feb..
02/02 TRILLIUM THERAPEUTICS : Outlines Anticipated Activities and Milestones for 2017
01/31 TRILLIUM THERAPEUTICS : Doses First Patient With TTI-621 in Phase 1 Solid Tumor ..
01/25 TRILLIUM THERAPEUTICS : January 2017 Corporate Presentation
2016 TRILLIUM THERAPEUTICS : Presents Initial Data From Ongoing Study of TTI-621 in P..
More news
Sector news : Bio Therapeutic Drugs
02/27DJSANOFI : Lonza to Invest CHF290 Million in New Plant in Switzerland
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
More sector news : Bio Therapeutic Drugs
Advertisement
Financials ( CAD)
Sales 2016 -
EBIT 2016 -33,0 M
Net income 2016 -32,1 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 0
Capi. / Sales 2017 0
Capitalization 63,5 M
More Financials
Income Statement Evolution
More Financials
Consensus 
Mean consensus BUY
Number of Analysts 4
Average target price 20,1  CAD
Spread / Average Target 148%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Niclas Stiernholm President, Chief Executive Officer & Director
Calvin R. Stiller Chairman
James T. Parsons Chief Financial Officer & Head-Investor Relations
Robert A. Uger Chief Scientific Officer
Eric Sievers Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
STEM CELL THERAPEUTICS..48
AMGEN, INC.19.39%129 711
CELGENE CORPORATION2.14%94 741
GILEAD SCIENCES, INC.-2.33%92 881
REGENERON PHARMACEUTIC..-1.66%39 573
ACTELION LTD22.36%28 883
More Results